Navigation Links
2014 Top 50 Big Biotech Partnering and M&A Deal Trends
Date:10/9/2014

NEW YORK, Oct. 8, 2014 /PRNewswire/ -- Summary

The Top 50 Big Biotech Partnering and M&A Deal Trends report provides comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

Description

The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big biotech companies
Over 300 charts showing a company's dealmaking activity since 2009, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2009 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

The Partnering Deals and Alliances with Big Biotech report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

This premier report provides all the information you require to better understand big biotech partnering.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives. Over 300 charts allow quick understanding of each big biotech companies dealmaking trends over the last four years.

This report contains over 1,500 links to online copies of actual partnering deals as recorded at Current Agreement, together with contract documents if submitted to the Securities Exchange Commission by big biotech and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of big biotech's dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big biotech companies based on 2013 pharmaceutical revenues and dealmaking activity since 2009.

Chapter 3 reviews the top partnering and M&A deals of 2009-2014 according to reported deal size.

Chapter 4 provides a summary on best practice on how to submit an opportunity to big biotech, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 5 lists forthcoming partnering events where valuable face to face meetings with big biotech provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 6. In-depth profiles of every big biotech company provide everything required to assess the suitability of a company as a prospective partner. Each profile includes a company overview, partnering activity according to deal type, phase of development, therapy area and technology type.

Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partner's negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This data driven report contains over 2,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In addition, contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In summary, the report provides the reader with the tools necessary to make successful contact with the right big biotech partners effectively and efficiently.

Benefits
Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big biotech companies
Over 300 charts showing a company's dealmaking activity since 2009, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2009 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 3,000 partnering deals, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Read the full report: http://www.reportlinker.com/p02405018-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>

SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
2. Puma Biotechnology Announces Completion of Private Placement
3. Animal Biotechnology - Technologies, Markets and Companies
4. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
5. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
6. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
7. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
8. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
9. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
10. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
11. Selexis SA to Present at Biotech Showcase 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2020)... ... June 23, 2020 , ... Nobilis Therapeutics, a biopharmaceutical ... has filed an Investigational New Drug application (IND) with the U.S. Food & ... drug candidate NBTX-001 in patients with panic disorder (PD). , "Adding a PD ...
(Date:6/11/2020)... ... June 09, 2020 , ... Reducing carbon emissions has been and will continue ... to stock market dips, ways to reduce CO2 is something we can’t avoid. ... of the biofuels being produced today are created from recycled cooking oil or crops. ...
(Date:5/28/2020)... BASEL, Switzerland (PRWEB) , ... May 28, 2020 ... ... for biopharmaceutical R&D, today announced the release of Genedata Screener ® 17.0, ... management of screening data from all in-vitro screening assay technologies. Genedata will host ...
(Date:5/21/2020)... ... May 19, 2020 , ... Eaton Square is pleased to announce its ... Company, a biotechnology and medical technology-focused strategy and M&A advisory firm. , This is ... States, linking US and Asia Pacific healthcare innovators with capital and investors. , Popper ...
Breaking Biology Technology:
(Date:7/1/2020)... ... 01, 2020 , ... Catalent, a global leader in clinical ... packaging facility in Minakuchi, located in the Shiga prefecture of Japan. , Operating ... the new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, serving ...
(Date:6/25/2020)... MANSFIELD, Mass. (PRWEB) , ... June 24, 2020 ... ... provider of cloud-based enterprise software and software-driven clinical data services that accelerate drug ... trials for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. ...
(Date:6/23/2020)... , ... June 23, 2020 , ... ... is pleased to announce the next event in a series of TOPIQ webinars, ... The TOPIQ series of webinars was developed in response to social distancing measures ...
Breaking Biology News(10 mins):